New developments in the pathogenesis of obesity-induced hypertension

Vasilios Kotsis1, Peter Nilsson, Guido Grassi

  • 1aHypertension-24 h ABPM ESH Center of Excellence, Papageorgiou Hospital, Aristotle University Thessaloniki, Greece bDepartment of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden cDepartment of Health Science, University of Milano-Bicocca, Milano, Italy and Istituto di Ricerche a Carattere Scientifico Multimedica IRCCS, Sesto San Giovanni, Milan dIstituto Auxologico Italiano, Milano, Italy eUniversity of Valencia and INCLIVA Research Institute and CIBERobn, Madrid, Spain fExperimental and Clinical Research Center, Kooperation zwischen dem Max-Delbrück-Centrum für Molekulare Medizin und der Medizinischen Fakultät der Charité, Berlin gAbteilung für Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Erlangen hInstitute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany i1st Department of Pediatrics, Hippokration Hospital, Aristotle University of Thessaloniki, Greece jDepartment of Medicine, Debrecen University, Hungary kSchool of Medicine and Pharmacology Royal Perth Hospital Unit, University of Western Australia, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.5K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.2K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
293
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
399